Public Employees Retirement System of Ohio Takes $1.23 Million Position in Xencor, Inc. (NASDAQ:XNCR)

Public Employees Retirement System of Ohio bought a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 53,397 shares of the biopharmaceutical company's stock, valued at approximately $1,227,000. Public Employees Retirement System of Ohio owned about 0.08% of Xencor as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in XNCR. Woodline Partners LP grew its stake in shares of Xencor by 0.3% in the fourth quarter. Woodline Partners LP now owns 845,916 shares of the biopharmaceutical company's stock valued at $19,439,000 after buying an additional 2,591 shares in the last quarter. Teza Capital Management LLC purchased a new position in Xencor during the 4th quarter valued at about $210,000. Sherbrooke Park Advisers LLC acquired a new position in Xencor in the 4th quarter valued at about $229,000. RTW Investments LP increased its stake in Xencor by 317.9% during the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after purchasing an additional 1,827,883 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in shares of Xencor by 452.4% during the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock worth $19,236,000 after purchasing an additional 685,557 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on XNCR. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wall Street Zen lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. William Blair initiated coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. Finally, Wedbush restated an "outperform" rating and set a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.50.

Insider Activity at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the firm's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.76% of the stock is owned by corporate insiders.

Xencor Stock Down 0.4%

NASDAQ XNCR traded down $0.04 during trading on Wednesday, reaching $9.10. 796,399 shares of the company's stock were exchanged, compared to its average volume of 668,903. The company has a 50 day moving average price of $9.05 and a two-hundred day moving average price of $15.95. The stock has a market cap of $647.66 million, a P/E ratio of -2.84 and a beta of 0.99. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The company had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm's quarterly revenue was up 104.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.11) EPS. On average, equities research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.